M3 Biotechnology

M3 Biotechnology is a clinical-stage company with a novel platform of disease-modifying regenerative small molecules.

M3 Biotechnology (M3) is a clinical-stage therapeutics company with a platform of novel disease-modifying regenerative small molecules being developed with the potential to stop disease progression and even restore lost function. While developing a pipeline of assets, M3 has now advanced a lead candidate, for Alzheimer’s disease(AD), to first-in-human Phase I clinical trials assessing safety, toxicity and tolerability while also evaluating a novel biomarker for AD. M3’s novel assets act on trophic factors of a highly conserved mechanism of action. The core technology and lead candidate has the potential to address neurodegenerative therapies broadly. The company has optimized a lead compound for a first indication in AD, launched clinical trials and expanded the therapeutics pipeline. Current drugs on the market for Alzheimer’s patients offer only symptomatic relief, whereas M3 anticipates the lead candidate will slow, halt and potentially restore lost function.